403 related articles for article (PubMed ID: 19442129)
1. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S
Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
[TBL] [Abstract][Full Text] [Related]
2. Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
Ferrer E; Gatell JM; Sanchez P; Domingo P; Puig T; Niubo J; Cortes C; Veloso S; Pedrol E; Leon A; Gutierrez M; Podzamczer D
AIDS Res Hum Retroviruses; 2008 Jul; 24(7):931-4. PubMed ID: 18671476
[TBL] [Abstract][Full Text] [Related]
3. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
[TBL] [Abstract][Full Text] [Related]
4. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
[TBL] [Abstract][Full Text] [Related]
5. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
6. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.
d'Ettorre G; Zaffiri L; Ceccarelli G; Andreotti M; Massetti AP; Vella S; Mastroianni CM; Vullo V
HIV Clin Trials; 2007; 8(3):182-8. PubMed ID: 17621465
[TBL] [Abstract][Full Text] [Related]
7. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
8. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
9. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Mira JA; López-Cortés LF; Barreiro P; Tural C; Torres-Tortosa M; de Los Santos Gil I; Martín-Rico P; Ríos-Villegas MJ; Hernández-Burruezo JJ; Merino D; López-Ruz MA; Rivero A; Muñoz L; González-Serrano M; Collado A; Macías J; Viciana P; Soriano V; Pineda JA
J Antimicrob Chemother; 2008 Dec; 62(6):1365-73. PubMed ID: 18854330
[TBL] [Abstract][Full Text] [Related]
11. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.
DART Virology Group and Trial Team
AIDS; 2006 Jun; 20(10):1391-9. PubMed ID: 16791013
[TBL] [Abstract][Full Text] [Related]
12. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
13. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
Rey D; Krebs M; Partisani M; Hess G; Cheneau C; Priester M; Bernard-Henry C; de Mautort E; Lang JM
J Acquir Immune Defic Syndr; 2006 Dec; 43(5):530-4. PubMed ID: 17057610
[TBL] [Abstract][Full Text] [Related]
14. Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
Ross LL; Rouse E; Gerondelis P; DeJesus E; Cohen C; Horton J; Ha B; Lanier ER; Elion R;
J Antimicrob Chemother; 2010 Feb; 65(2):307-15. PubMed ID: 20008905
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
[TBL] [Abstract][Full Text] [Related]
16. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
[TBL] [Abstract][Full Text] [Related]
17. Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
d'Ettorre G; Mastroianni CM; Massetti AP; Lichtner M; D'Agostino C; Vullo V
AIDS; 2005 May; 19(8):841-2. PubMed ID: 15867503
[No Abstract] [Full Text] [Related]
18. Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
Mastroianni CM; d'Ettorre G; Vullo V
Expert Opin Pharmacother; 2006 Nov; 7(16):2233-41. PubMed ID: 17059380
[TBL] [Abstract][Full Text] [Related]
19. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Van Kasteren ME; Bravenboer B; Ten Kate RW; Groeneveld PH; van der Werf TS; Gisolf EH; Richter C
AIDS Patient Care STDS; 2010 Jun; 24(6):361-6. PubMed ID: 20515418
[TBL] [Abstract][Full Text] [Related]
20. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
